Fundraising FoxProta Therapeutics
Melbourne, AU · 2 known investors
Find your way into Prota Therapeutics
Sign up to find every way you can get introduced to Prota Therapeutics
- Your email: who you already know at Prota Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Prota Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Prota Therapeutics is a late clinical-stage biotech company developing allergen oral immunotherapies to treat food allergies, with a lead phase-3-ready product (PRT120) targeting peanut allergy. Its technology originated from research led by Professor Mimi Tang at the Murdoch Children's Research Institute in Melbourne, Australia.
Founders & leadership
Investors · 2
How we know: OneVentures's portfolio page · funding news · sprim.net · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 1
Funding
SEC filings, press & company announcements- Undisclosed amountSeries A1Jan 2024
SPRIM Global Investments (SGI) (lead), OneVentures
Source ↗ - Undisclosed amountSeries AJan 2024Source ↗
- Undisclosed amountSeries BJun 2017Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Prota Therapeutics do?
- Prota Therapeutics is a late clinical-stage biotech company developing allergen oral immunotherapies to treat food allergies, with a lead phase-3-ready product (PRT120) targeting peanut allergy. Its technology originated from research led by Professor Mimi Tang at the Murdoch Children's Research Institute in Melbourne, Australia.
- Who founded Prota Therapeutics?
- Prota Therapeutics was founded by Mimi Tang.
- Who are Prota Therapeutics's investors?
- Prota Therapeutics's investors include OneVentures.
- Where is Prota Therapeutics headquartered?
- Prota Therapeutics is headquartered in Melbourne, AU.